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Introduction: Stage IIIA non-small cell lung cancer (NSCLC) with
ipsilateral mediastinal lymph node metastases (N2) is a heteroge-
neous disease with differing prognoses. In this study, we retrospec-
tively investigated the prognostic value of the expression of 10
molecular markers in 87 patients with stage IIIA pN2 NSCLC
treated with radical surgery.
Methods: Primary tumor tissue microarrays (TMAs) were con-
structed and sections used for immunohistochemical analysis of
epidermal growth factor receptor, ErbB-2, c-kit, cyclooxygenase-2,
survivin, bcl-2, cyclin D1, cyclin B1, metalloproteinase (MMP)-2,
and MMP-9. Univariate and multivariate analyses and unsupervised
hierarchical clustering analysis of clinical pathologic and immuno-
staining data were performed.
Results: Bcl-2 (p  0.0001) and cyclin D1 (p  0.015) were more
highly expressed in squamous cell carcinoma (SCC), whereas
MMP-2 (p  0.009), MMP-9 (p  0.005), and survivin (p  0.032)
had increased expression in other histologic subtypes. In univariate
analysis, SCC histology and cyclin D1 expressions were favorable
prognostic factors (p  0.015 and p  0.0001, respectively); by
contrast, MMP-9 expression was associated with worse prognosis (p
0.042). In multivariate analysis, cyclin D1 was the only positive
prognostic factor (p  0.0001). Unsupervised hierarchical clustering
analysis of TMA immunostaining data identified five distinct clusters.
They formed two subsets of patients with better (clusters 1 and 2) and
worse (clusters 3, 4, and 5) prognoses, and median survival of 51 and
10 months, respectively (p  0.0001). The better prognosis subset
mainly comprised patients with SCC (80%).
Conclusions: Hierarchical clustering of TMA immunostaining data
using a limited set of markers identifies patients with stage IIIA pN2
NSCLC at high risk of recurrence, who may benefit from more
aggressive treatment.
Key Words: Stage IIIA NSCLC, Prognostic markers, Tissue mi-
croarrays, Unsupervised hierarchical clustering analysis.
(J Thorac Oncol. 2010;5: 1354–1360)
Patients with stage IIIA non-small cell lung cancer(NSCLC) involving ipsilateral mediastinal nodes (pN2)
represent a heterogeneous population with differing clinical
presentations and prognoses, ranging from those with inci-
dental N2 disease found after surgery by pathologic exami-
nation of the resected tissue, to patients with bulky or fixed
multistation, pathologically confirmed N2 disease that is
clearly unresectable. Treatment guidelines for stage IIIA pN2
NSCLC are evolving,1 and the management of these patients
remains challenging. Although the superiority of multimodal-
ity treatment is well established, the optimal combination and
sequence of chemotherapy, surgery, and radiation therapy are
still controversial. Platinum-based combination chemoradio-
therapy is the recommended primary treatment for patients
with N2 disease detected at staging, although surgery com-
bined with either adjuvant or neoadjuvant chemotherapy is
acceptable in selected patients.1,2 Nevertheless, overall sur-
vival for patients with stage IIIA pN2 NSCLC is still unsat-
isfactory, with a 5-year survival rate of just 22%.3
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Subclassification of this heterogeneous population, and
the identification of distinct prognostic subgroups, may allow
the optimization of clinical trial design, with the potential to
improve treatment outcomes. As a first step in this direction,
a revision of nodal (N) descriptors in NSCLC was recently
proposed by the International Association for the Study of
Lung Cancer. This establishes the following three prognostic
groups: single-zone N1 (N1a); either multiple zone N1 (N1b)
or single-zone N2 (N2a); and multiple zone N2 lymph node
disease.3 Preliminary validation of this new classification has
been reported,4 but larger prospective studies are required.
Molecular markers, including those involved in the regulation
of cell proliferation, differentiation, apoptosis, and in inva-
sion, angiogenesis, and metastasis, have the potential to
further refine this process. The assessment of the expression
pattern of such molecules in each individual tumor sample by
molecular biology or traditional immunohistochemistry has
been relatively expensive and time consuming, but this is
changing. Already these limitations can be overcome by the
use of immunohistochemistry on tissue microarrays (TMAs),
a useful tool for the rapid and efficient analysis of multiple
markers on large numbers of paraffin-embedded tissues.5,6
Using TMA technology, samples from hundreds of different
tumors can be analyzed at the same time to assess the
expression profile of potentially relevant prognostic markers
and/or therapeutic targets.
In this study, we used TMA to evaluate the expression
and prognostic significance of a panel of 10 molecular mark-
ers in patients with stage IIIA pN2 NSCLC treated surgically
with curative intent who did not receive adjuvant chemother-
apy or biologic therapies. The panel of markers included cell
cycle regulators (cyclin D1 and cyclin B1), growth factor
receptors (c-erbB-1 and c-erbB-2, c-kit), antiapoptotic factors
(bcl-2 and survivin), an enzyme involved in the arachidonic
acid cascade with angiogenic properties (cyclooxygenase-2
[COX-2]), and proteins involved in the degradation of the
extracellular matrix metalloproteinases (MMPs)-2 and -9.
These 10 markers were chosen among the ones that were
targets for biologic agents under evaluation in clinical trials at
the time this study was designed, and for which antibodies
suitable for immunohistochemistry were available.7–12
PATIENTS AND METHODS
Patients and Clinical Samples
A search of the prospective S. Maria della Misericordia
General Hospital Thoracic Surgery database identified 196
consecutive patients with stage IIIA pN2 NSCLC who un-
derwent radical surgery at that Center between 1985 and
1997. Eighty seven of these patients satisfied the following
additional selection criteria: (i) at least 4 weeks survival after
surgery; (ii) no preoperative radiotherapy or chemotherapy;
(iii) microscopically negative resection margins (R0); and
(iv) availability of archival formalin-fixed paraffin-embedded
tumor tissue suitable for TMA preparation. Regional lymph
node staging was performed by systematic mediastinal lymph
node sampling; nodal stations were classified according to
Naruke’s map.13 Routine preoperative staging included clin-
ical examination, chest radiography, and computed tomogra-
phy scan of the chest and upper abdomen; positron emission
tomography was not available at the time. Patients did not
receive adjuvant chemotherapy. Demographic, clinical, and
pathologic characteristics are listed in Table 1.
Formalin-fixed, paraffin-embedded primary tumor tis-
sue samples were retrieved from the archives of the local
Histopathology Department. To confirm the diagnosis of
NSCLC, histologic slides from all patients were indepen-
dently reviewed by two pathologists (V.C. and C.A.B.).
Tumor size and nodal status were obtained from the original
pathology reports. The tumors were staged according to the
International Union Against Cancer’s tumor node metastasis
classification.14 Histologic subtype and grade were classified
according to the World Health Organization guidelines.15
Survival data were available for all patients from hospital
records or local registries. Ethics approval was obtained
according to local practice.
TMA Construction
TMA were constructed as described by Kononen et al.5
Briefly, 4-m sections stained with hematoxylin and eosin
were prepared from each formalin-fixed paraffin-embedded
block to select the most representative tumor areas to be
TABLE 1. Clinical and Pathological Characteristics (n  87)
Parameter n (%)
Age, yr
Median 62
Range 35–74
Gender
Male 71 (82)
Female 16 (18)
Histology
Adenocarcinoma, BAC 33 (38)
Squamous cell carcinoma 50 (58)
Large cell carcinoma 4 (5)
pT
T1 25 (29)
T2 48 (55)
T3 14 (16)
Number of N2 lymph node stations involved
1 45 (52)
2 23 (26)
3 16 (18)
4 2 (2)
5 1 (1)
Surgical Intervention
Lobectomy 39 (45)
Pneumonectomy 48 (55)
Postoperative thoracic radiotherapy
Yes 44 (51)
No 23 (26)
Unknown 20 (23)
Survival, mo
Median 13.2
Range 1.1–215
BAC, bronchioloalveolar carcinoma.
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sampled. Tumor tissue cylinders with a diameter of 1.5 mm
were then punched from the selected area of each donor block
using a tissue arraying precision instrument (Beecher Instru-
ments, Sun Prairie, WI) and arrayed into a recipient paraffin
block. Duplicate tissue cores from each donor block were
obtained. Four-micrometer sections of these tissue arrays
were prepared and used for immunohistochemical analysis.
Appropriate tissues known to express the antigens under
study were processed in parallel and used as positive controls.
Immunohistochemistry
Standard indirect immunoperoxidase staining was per-
formed for the detection of epidermal growth factor receptor
(EGFR), ErbB-2, c-kit, COX-2, survivin, bcl-2, cyclin D1,
cyclin B1, and MMP-2 and -9. Protocols for antigen retrieval,
antibody concentrations, and detection systems are summa-
rized in Table 2. Immunoreactivity was expressed as percent-
age of positive cells and staining intensity. To classify the
individual sample as positive or negative, cutoff values were
predefined, as reported in Table 2. All slides were evaluated
and scored independently by two pathologists (V.C. and
C.A.B.), without knowledge of clinical outcome; in the event
of disagreement, the pathologists reviewed the slides together
and reached a consensus.
Statistical Analysis
We considered the following clinical pathologic vari-
ables: age (64 versus 65 years), gender, histology (squa-
mous versus other), pT stage, surgical procedure (lobectomy
versus pneumonectomy), number of N2 stations involved,
and postoperative radiotherapy (yes versus no versus un-
known). Overall survival was defined as the time interval
between the date of surgery and death from any cause.
Patients still alive at the time of the final analysis were
censored at the date of last contact. At the time of study
analysis, survival data were available for all patients. Median
potential follow-up defined as time from date of surgery to
date of analysis was 11.7 years (range, 5.1–17.9 years);
median follow-up for the 13 patients alive was 9.5 years
(range, 5.3–17.7 years).
Fisher’s exact test was used to assess the associations
between each molecular marker and histology. Univariate
survival analyses were performed by Kaplan-Meier estimates
and log-rank tests; binary scores (i.e., as positive or negative)
for immunohistochemistry data were used, as described in
Table 2. The p values  0.05 are statistically significant.
Multivariate assessment of overall survival was performed
using the stepwise Cox proportional hazard model with back-
ward elimination at p less than 0.1; all clinical variables and
biologic markers were included in the model.
Unsupervised hierarchical clustering analysis was car-
ried out with the CLUSTER 3.0 software program and results
were visualized with the TREEVIEW 1.0.10 program16,17;
both CLUSTER and TREVIEW software are available at
http://rana.lbl.gov/eisen. All raw score data were used for
clustering analysis. The analyses were “unsupervised” with
no assumptions made with regards to patients’ clinical or
pathologic characteristics.
RESULTS
Immunohistochemistry
EGFR was expressed in 18% of cases; ErbB-2, 18%;
c-kit, 7%; COX-2, 37%; survivin, 71%; bcl-2, 22%; cyclin
D1, 27%; cyclin B1, 64%; MMP-2, 23%; and MMP-9, 49%.
Bcl-2 and cyclin D1 were more expressed in squamous cell
carcinomas (SCCs) (p 0.0001 and p 0.015, respectively),
whereas MMP-2, MMP-9, and survivin displayed increased
expression levels in the other histologic types (p  0.009,
p  0.005, and p  0.032, respectively).
TABLE 2. Antibodies and Procedures
Marker Clone Sourcea Dilution Antigen Retrival Incubation
Detection
Systemb
Staining
Pattern
Staining
Assessmentc
Negative Positive
EGFR F4 Sigma 1:500 None O/N 1 M 0/ /
c-erbB-2 CB-11 Cell Marque Prediluted 10 mM citrate pH 6.0 30 min 2 M 0/d /d
c-kit 0G011Ae Dako 1:100 10 mM citrate pH 6.0 O/N 1 M 10% 10%
COX-2 Sc-7951e Santa Cruz 1:400 10 mM citrate pH 7.3 120 min 1 C 0/ /
Survivin 469e Abcam 1:50 10 mM citrate pH 6.0 O/N 3 C 50% 50%
Bcl-2 100/D5 Ventana Prediluted 10 mM citrate pH 7.3 30 min 2 C 0/ /
Cyclin D1 DCS-6 Dako 1:100 10 mM citrate pH 6.0 O/N 1 N 10% 10%
Cyclin B1 V152 Dako 1:50 10 mM citrate pH6.0 O/N 1 N and C 15% 15%
MMP-2 A-Gel VC2 Neomarkers 1:50 None O/N 3 C 0/ /
MMP-9 AB-9e Neomarkers 1:50 None O/N 3 C 0/ /
a Manufacturers locations: SIGMA (St Louis, MO); Cell Marque (Rocklin, CA); DAKO (Glostrup, Denmark); Santa Cruz (Santa Cruz, CA); Abcam (Cambridge, MA); Ventana
Medical Systems (Tucson, AZ); Neomarkers for Lab Vision Corporation (Fremont, CA).
b Detection system: 1, ABC Elite (Vector Laboratories, CA); 2, High-intensity DAB detection kit (Ventana Medical Systems, Tucson, AZ); 3, Dako Cytomation LSAB (DAKO,
Carpinteria, CA).
c 0, 20% of tumor cells reactive; , 20% of tumor cells (weak); , 20% of tumor cells (moderate); , 20% of tumor cells (strong).
d 0, 10% of tumor cells reactive; , 10% of tumor cells (weak); , 10% of tumor cells (moderate); , 10% of tumor cells (strong).
e Polyclonal antibody.
EGFR, epidermal growth factor receptor; O/N, overnight; min, minutes; M, membranous; N, nuclear, C, cytoplasmic; COX, cyclooxygenase; MMP, matrix metalloproteinase.
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Univariate and Multivariate Analysis of Clinical
Pathologic and Immunostaining Data
Overall survival rates were 56%, 21%, and 11% at 1, 5,
and 10 years, respectively; median survival was 13.2 months
(74 events observed).
In univariate analysis, squamous cell histology was
associated with better prognosis (p  0.015); age, gender,
type of surgery, number of N2 stations involved, and post-
operative thoracic radiotherapy did not show a statistically
significant correlation with survival. Among molecular mark-
ers, the expression of cyclin D1 was a favorable prognostic
factor (p  0.0001), whereas MMP-9 expression was asso-
ciated with a worse prognosis (p  0.042, Figure 1).
Multivariate analysis using the stepwise Cox propor-
tional hazard model confirmed cyclin D1 as an independent
positive prognostic factor (hazard ratio [HR]  0.22, 95%
confidence interval [CI]  0.12–0.42, p  0.0001). Among
the remaining markers, EGFR and survivin showed a trend
toward better and worse survival, respectively (HR  0.55,
95% CI  0.29–1.06, p  0.075 and HR  1.61, 95% CI 
0.94–2.77, p  0.084, respectively). Multivariate analysis by
histologic subtype confirmed cyclin D1 positivity as the only
significant prognostic factor in the squamous histology group
(n  50), predicting for better outcome (HR  0.30, 95%
CI  0.14–0.61, p  0.0009). In the nonsquamous histology
subset (n  37), female gender and COX-2 expression were
independent positive prognostic factors (HR  0.42, 95%
CI  0.17–1.00, p  0.049 and HR 0.28, 95% CI 0.11–0.72,
p  0.008, respectively), whereas MMP-2 expression and
increasing number of N2 lymph node stations involved were
associated with worse prognosis (HR  2.35, 95% CI 
1.06–5.24, p  0.036 and HR  0.54, 95% CI  0.34–0.86,
p  0.01, respectively). In a multivariate analysis stratified
according to postoperative radiotherapy status (yes or no),
cyclin D1 was confirmed as a positive prognostic factor for
both patients who received (n  44; HR  0.066, 95% CI 
0.007–0.636; p  0.0002) and who did not receive postop-
erative radiotherapy (n  23; HR  0.115, 95% CI 
0.037–0.359; p  0.0187). In the radiotherapy group, EGFR
positivity was also a positive prognostic factor (HR  0.397;
95% CI  0.164–0.961; p  0.04), whereas MMP-9 was
associated with poorer outcome in the radiotherapy naive
group (HR  3.679; 95% CI  1.167–11.602; p  0.0262).
Unsupervised Hierarchical Clustering Analysis
of Immunostaining Data
To identify more complex associations of the 10 biologic
markers, unsupervised hierarchical clustering analysis was per-
formed on the immunostaining data. Based on the similarity of
biomarker expression profiles, the algorithm ordered the 87
cases in a clustergram (Figure 2). In the clustergram, the 10
biomarkers data are represented on the horizontal axis and the 87
cases on the vertical axis. In the resulting neighbor-joining tree,
cases with similar expression patterns are adjacent and the length
of horizontal dendrogram branches is inversely proportional to
the expression profile similarity of the biomarkers. The analysis
produced a dendrogram with five well-defined clusters (Figure 2).
The tree structure suggests a further subdivision of cluster 3 into
two subclusters, 3a and 3b.
The dendrogram structure shows the relationships be-
tween cases displaying similar histologic/molecular data and
tumor type. SCCs are the major histologic type in cluster 1 (6 of
6 cases) and cluster 2 (17 of 23); in these two clusters, a rather
homogeneous immunohistochemical profile was observed. De-
spite a predominance of SCCs (16 of 25 cases), cluster 3 is
characterized by immunohistochemical heterogeneity in both
subclusters. Group 4 and 5 mostly comprised nonsquamous cell
carcinomas and are characterized by rather homogeneous im-
munohistochemical profiles, as shown by the reduced length of
the horizontal components of the dendrogram branches.
FIGURE 1. Kaplan-Meier survival
curves for all patients (A) and ac-
cording to (B) squamous cell carci-
noma (SCC) versus nonsquamous
histology, and expression of (C) cy-
clin D1, and (D) MMP-9 by immu-
nohistochemistry. MMP, matrix
metalloproteinase.
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FIGURE 2. Clustergram graphically representing unsupervised clustering analysis on immunostaining data with 10 bi-
omarkers on TMAs of 87 cases with stage IIIA pN2 non-small cell lung cancer (NSCLC). Each row represents a single
case. Each column represents a single marker. Bright green, negative staining (score 0); dark green, weak staining
(score ); brown, moderate staining (score ); red, strong staining (score ). The dendrograms on the left of the
clustergram represent the relatedness of the immunoprofiles of individual cases; the longer the horizontal dendrogram
arm, the greater the difference in immunoprofiles. The horizontal bars on the right of the clustergram represent the sur-
vival of each individual patient, calculated from the date of radical surgery to the date of death or to the date of final
analysis, whichever came first; the color of each column identifies squamous cell carcinoma (SCC, blue) versus nonsqua-
mous cell carcinomas (NSCC, yellow).
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Based on the expression profile of the 10 biomarker
panel, a significant correlation between clusters and survival
was observed in our series: patients in cluster 1 and 2 (n 
29) had a significantly longer survival than patients in clusters
3–5 (n  58) (Figure 3). Median survival time in these two
subsets was 51 versus 10 months, respectively (p  0.0001).
DISCUSSION
This study demonstrates the feasibility of identifying
patients with high-risk stage IIIA pN2 NSCLC by unsuper-
vised hierarchical clustering analysis of immunostaining data
of a limited number of markers. This is an exploratory study
and larger studies will be necessary to confirm our findings
and validate our panel of markers.
We selected a panel of 10 markers relevant to the
control of cell proliferation, apoptosis, angiogenesis, and
tumor invasion, including EGFR, ErbB-2, c-kit, COX-2,
survivin, bcl-2, cyclin D1, cyclin B1, and MMP 2 and 9.
These markers have already been assessed individually by
immunohistochemistry as prognostic markers in NSCLC;
however, the prognostic value of each individual marker is
not consistent among different studies.18–20 This is not sur-
prising because the development of NSCLC is driven by
multiple somatic mutations resulting in a complex cancer
genome and gene expression profile. The expression of indi-
vidual genes is probably not appropriate to address this
complexity, and the use of an approach based on the expres-
sion of several genes is likely to be preferable.
Several additional factors may also contribute to the
inconsistency in reports of prognostic markers. These factors
relevant to individual studies include heterogeneity of the
study population in terms of clinical pathologic characteris-
tics; bias in patient selection, especially in retrospective
studies; differences in specimen handling and molecular tech-
niques for the detection and quantification of markers; and
differences in treatment. Many studies are also small and
statistically underpowered, potentially leading to false-nega-
tive results. This study avoided many, but not all, of these
limitations. Heterogeneity of the patient population was min-
imized by carefully defining the subjects to be studied.
Similarly, although retrospective, our study avoided bias by
including sequential patients. Being a single-center study,
differences in sample handling and processing were also
minimized. Similarly, patients were under a single surgical
team, so operative treatment was uniform and outcomes were
not affected by adjuvant chemotherapy that was not in use at
the time. Although our sample size was modest, we were able
to identify statistically significant relationships.
In our series, cyclin D1 expression was the only inde-
pendent prognostic factor in multivariate analysis, which was
associated with more favorable outcome (p 0.0001). Cyclin
D1 plays an important role in the regulation of G1-to-S phase
transition and is also a cofactor for many transcription fac-
tors.21 The expression of cyclin D1 by immunohistochemistry
and its prognostic value in NSCLC have been extensively
investigated with conflicting conclusions22; our results are
concordant with the largest studies reporting cyclin D1 as
positive prognostic factor in NSCLC.23–25 Differences among
patient populations, use of different antibodies, and also the
adoption of different criteria to classify cyclin D1 positivity
may explain different conclusions. This area is further com-
plicated by the existence of two isoforms of cyclin D1 (a and
b) as a result of alternative splicing26; recent reports suggest
that only cyclin D1b is associated with clinical outcome.21,27
As most immunohistochemistry studies to date, including
ours, have used antibodies recognizing total cyclin D1 or the
C terminus of cyclin D1a,21 the association between cyclin
D1b and clinical outcome in NSCLC has not been adequately
addressed, and large well-designed studies are required.
We also performed a multivariate analysis by histologic
subtype in which cyclin D1 expression was confirmed as
positive prognostic factor for SCC but not for nonsquamous
histology. In the nonsquamous histology subset, female gen-
der and COX-2 expression were the positive prognostic
factors, and MMP-2 expression and increasing number of N2
lymph node stations were negative prognostic factors. This
was not a preplanned analysis and its statistical power is
reduced by the smaller sample size; these observations need
to be confirmed in larger series.
A previous retrospective study by Au et al.28 investi-
gated the prognostic value of a panel of 18 molecular markers
by immunohistochemistry on TMA in 284 cases of NSCLC.
Three markers assessed in that study were included in this
analysis, namely cyclin D1, ErbB-2, and bcl-2; their panel
also included six markers of neuroendocrine differentiation.
Interestingly, univariate analysis indicated cyclin D1 and
ErbB-2 as prognostically relevant only in the adenocarcinoma
group, being associated with better outcome. Hierarchical
clustering analysis of immunostaining data for the 18 markers
identified four distinct clusters; in contrast to this study, there
was no significant difference in disease-specific survival
between the different clusters (p  0.57). It is possible that
the presence of a significant proportion of markers likely to
be relevant only in a histologic subtype of NSCLC decreased
the prognostic power of their study. By contrast, our panel of
10 markers was not selected on the basis of them being
specific for a specific histologic subtype. This may explain
why in our study, analysis of immunohistochemistry data did
showed a statistically significant difference between the two
subsets (p  0.0001). Importantly, taken together the two
studies support the feasibility of hierarchical clustering anal-
ysis of immunohistochemistry data on TMA for the stratifi-
cation of patients with NSCLC.
FIGURE 3. Overall survival by clusters, based on hierarchi-
cal clustering analysis.
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The integration of clinical parameters with molecular
profiling data will become increasingly important in the
management of patients with NSCLC, to make an accurate
diagnosis and to tailor treatment decision to the individual
patient. We have shown that immunohistochemistry can iden-
tify patients with stage IIIA pN2 NSCLC at high risk of
recurrence, who may benefit from more aggressive treatment
or novel therapies. Notwithstanding the emergence of novel
gene expression techniques, we believe that applying the
“old” technique of immunohistochemistry, which is robust
and widely available, to TMA may have an important role in
optimizing therapy for patients with NSCLC.
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